Vital Therapies reported $-21435000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Dynavax Technologies DVAX:US $ 127.67M 96.2M
Enanta Pharmaceuticals ENTA:US $ -33847000 3.44M
Epizyme EPZM:US $ -50926000 360K
Insmed INSM:US $ -100938000 513K
Intercept Pharmaceuticals ICPT:US $ -13363000 3.09M
Mirati Therapeutics MRTX:US $ -177205000 7.01M
Omeros OMER:US $ -35046000 65.69M
Orasure Technologies OSUR:US $ -16014000 6.68M
Regulus Therapeutics RGLS:US $ -6569000 391K
Revance Therapeutics RVNC:US $ -62221000 617K
Ultragenyx Pharmaceutical RARE:US $ -141593000 4.96M
United Therapeutics UTHR:US $ 201.8M 86.2M
Vital Therapies VTL:US $ -21435000 286K
Xoma XOMA:US $ -4767000 2.7M